Calmare Therapeutics Incorporated announced unaudited consolidated earnings results for the first quarter ended March 31, 2016. Revenues from the commercial sale and shipment of Calmare® pain therapy devices (Devices)for the three months ended March 31, 2016 were $56,000 as compared with $8,000 for the three months ended March 31, 2015. Net loss for the three months ended March 31, 2016 was $878,000 or $0.03 per basic and diluted share as compared with a net loss of $1,004,000 or $0.04 for the three months ended March 31, 2015. Operating loss was $585,351 against $815,801 a year ago. Loss before income taxes was $877,917 against $1,004,251 a year ago. Net cash used in operating activities was $523,870 against $294,744 a year ago.